US-based Medtronic has completed the acquisition of Sapiens Steering Brain Stimulation (Sapiens SBS), a Dutch developer of deep brain stimulation (DBS) technologies for approximately $200m.
With the acquisition, Medtronic strengthens its capabilities in the modulation of brain function, an important field of medicine.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sapiens SBS is focused in developing DBS system that features an advanced DBS lead with 40 individual stimulation points.
The system is designed to provide more precise stimulation of the intended target in a patient’s brain and might result in reduced procedure time and fewer stimulation-induced side-effects.
As a result of the acquisition, Medtronic will use Sapiens Eindhoven facility as a global research and development centre for its Neuromodulation business to improve the current R&D operations.
Medtronic Brain Modulation business vice-president and general manager Dr Lothar Krinke said: “This acquisition broadens our neuroscience leadership position with innovative brain modulation technology that, along with our comprehensive portfolio of DBS solutions, may one day transform the way physicians are able to treat patients with neurodegenerative diseases like Parkinson’s disease and essential tremor.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn order to integrate these technologies into an expanded portfolio of DBS products within Medtronic’s Neuromodulation business, both the firms will work together to finalise product development as well as initiate clinical research.
Sapiens SBS chief executive officer Jan Keltjens said: “Since 2011, Sapiens SBS employees have worked tirelessly to develop an advanced deep brain stimulation system.
“We are excited to join Medtronic, and look forward to collectively working to bring this and other novel technologies and therapies to neuromodulation patients worldwide that could benefit from them.”
The Medtronic DBS therapy has received approval in the US and Europe, to treat disabling symptoms of essential tremor, advanced Parkinson’s disease and chronic intractable primary dystonia.
Image: Medtronic world headquarters in Minneapolis, US. Photo: courtesy of Medtronic, Inc.
